What is he best known for?
The fields of study he is best known for:
Paul Klenerman focuses on Immunology, Virology, Cytotoxic T cell, CD8 and Immune system.
His Hepatitis C virus, Antigen, T cell, Immunity and Human leukocyte antigen study are his primary interests in Immunology.
His research in Virology is mostly concerned with Virus.
His Cytotoxic T cell research is multidisciplinary, incorporating perspectives in Molecular biology and Effector.
His CD8 research integrates issues from T lymphocyte, Mucosal associated invariant T cell, T-cell receptor, Phenotype and Cell biology.
His Immune system research is multidisciplinary, relying on both Interferon, Cell culture, Antibody and Hepatitis B virus.
His most cited work include:
- PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression (2076 citations)
- Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. (1423 citations)
- Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus (1185 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Immunology, Virology, Cytotoxic T cell, Immune system and CD8.
His Immunology study focuses mostly on T cell, Antigen, Hepatitis C, Immunity and CTL*.
His Virology research is multidisciplinary, incorporating elements of Epitope and Human leukocyte antigen.
His Cytotoxic T cell research incorporates elements of Major histocompatibility complex and Cell biology.
The CD8 study combines topics in areas such as Phenotype and Mucosal associated invariant T cell, T-cell receptor.
His studies deal with areas such as Antibody and Lymphocytic choriomeningitis as well as Virus.
He most often published in these fields:
- Immunology (55.51%)
- Virology (45.25%)
- Cytotoxic T cell (27.12%)
What were the highlights of his more recent work (between 2018-2021)?
- Immunology (55.51%)
- Immune system (27.25%)
- Virology (45.25%)
In recent papers he was focusing on the following fields of study:
Immunology, Immune system, Virology, CD8 and T cell are his primary areas of study.
His Immunology research includes elements of Receptor and In vivo.
Paul Klenerman has researched Immune system in several fields, including Cell, Cytokine and Antigen.
The Virus, Vaccination and Hepatitis C virus research Paul Klenerman does as part of his general Virology study is frequently linked to other disciplines of science, such as Severe acute respiratory syndrome coronavirus 2, therefore creating a link between diverse domains of science.
He combines subjects such as Cytotoxic T cell and Cell biology with his study of CD8.
His research in T cell intersects with topics in Immune checkpoint, Cancer research, Peripheral blood mononuclear cell, Disease and Epitope.
Between 2018 and 2021, his most popular works were:
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (671 citations)
- Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) (345 citations)
- Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. (256 citations)
In his most recent research, the most cited papers focused on:
The scientist’s investigation covers issues in Antibody, Immunology, CD8, Virology and T cell.
His Immunology research includes themes of Disease and In vivo.
Paul Klenerman interconnects Cytotoxic T cell, Cell biology and T-cell receptor in the investigation of issues within CD8.
His work deals with themes such as Phenotype and Autoimmunity, which intersect with Cytotoxic T cell.
His study in the field of Virus and Viral load is also linked to topics like Severe acute respiratory syndrome coronavirus 2.
His T cell course of study focuses on Antigen and Immune checkpoint and Single-cell analysis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
